Navigation Links
AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
Date:6/12/2008

AMSTERDAM, June 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has concluded enrollment and treated the last patient in the pivotal trial for it's lead product AMT-011 (Glybera(R)) for Hyperlipoproteinemia, a seriously debilitating and potentially lethal disease. After recent preparatory meetings with the rapporteur countries Germany and the United Kingdom of the European Medicines Agency (EMEA), AMT expects to file the Marketing Authorization Dossier with EMEA not later than the fourth quarter of 2008.

AMT has developed AMT-011 as a cure for patients with the rare genetic disorder Hyperlipoproteinemia (HPL) type I, also known as LPL-deficiency. These patients have extremely high fat levels in their blood resulting in recurrent and potentially lethal pancreatitis as well as an increased risk of cardiovascular complications and diabetes. Because of a defective gene HPL-patients do not produce an enzyme that normally breaks down fats in the blood. Currently, there is no effective treatment or cure for this seriously debilitating and potentially lethal disease.

AMT-011 is a gene therapy product designed to insert a healthy gene into the patient's body to replace the defective gene. The product is administered by a series of injections into muscle tissue after which the body starts to make the missing enzyme again. The advantage of this therapy is its potential to cure a disease instead of just treating the symptoms. AMT expects to finish the ongoing clinical trial with AMT-011 according to plan.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Synbiotics Corporation Announces Human Submission for FluDetect(R)
3. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
4. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
5. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
6. Indevus Announces Submission of New Drug Application
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
10. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
11. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
(Date:1/23/2015)... January 23, 2015 Heptares Therapeutics, the clinical-stage ... announce that the Malcolm Campbell Memorial Prize for ... President of Chemistry), Fiona Marshall (Chief Scientific Officer ... and co-founder) for the seminal contributions to GPCR drug discovery ...
(Date:1/22/2015)... 2015  BiOptix is pleased to announce the appointment of ... Chemistry and Biochemistry. Scott joins the company after previous scientific ... throughout the course of his nearly 20 year career ... a nationally recognized thought leader in the biosensor field ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... 2011 Zimmer Holdings, Inc. (NYSE: ZMH ; ... earnings conference call will be broadcast live over the Internet ...  A news release detailing the quarterly results will be made ... conference call. The live audio webcast can ...
... 2011 Lanx ® , Inc., a privately held ... devices for spinal surgery, today announced the launch of ... American Association of Neurological Surgeons (AANS) Annual Meeting, Denver, ... minimally invasive fixation alternative to pedicle screws, intended to ...
Cached Medicine Technology:Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2011 Results 2Lanx®, Inc. Announces Launch of Concero™ Facet Screw System for Spinal Fusion 2
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... , WEDNESDAY, July 13 (HealthDay News) -- People ... but virtual reality- and physical reality-based therapies may provide ... research suggests. In conducting the study, scheduled for ... of Physical Medicine and Rehabilitation , researchers assigned tasks ...
... development assistance from the Georgia Tech Research Institute (GTRI) ... an Atlanta-based company is developing what it hopes will ... hundreds of millions of people who wear glasses or ... To be used by optometrists and ophthalmologists, the ...
... News) -- For patients taking the heart rhythm drug amiodarone ... incidents of thyroid dysfunction than the brand-name medication, researchers report. ... difference between the two drugs, according to the report released ... . Amiodarone, a drug used to control arrhythmia -- ...
... from two major HIV prevention trials announced favorable results of ... of these trials, the Partners PrEP Study, has provided the ... both studies will need to be fully evaluated before it ... major trial that is ongoing. Investigators for VOICE Vaginal ...
... , WEDNESDAY, July 13 (HealthDay News) -- A ... fight the H1N1 epidemic in 2009 may not have boosted ... all. Guillain-Barre is a rare disorder, which causes a ... weakness and even paralysis. In 1976, a vaccine used ...
... (OA) is a leading cause of disability in the ... to raise awareness and increase knowledge of OA among ... American Journal of Nursing and the National Association of ... in the Prevention and Management of Osteoarthritis" on Thursday, ...
Cached Medicine News:Health News:'Virtual Reality' May Help in Parkinson's Therapy 2Health News:R&D collaboration focuses on new system for measuring and improving human vision 2Health News:R&D collaboration focuses on new system for measuring and improving human vision 3Health News:R&D collaboration focuses on new system for measuring and improving human vision 4Health News:Generic, Brand-Name Heart Drugs Seem to Have Same Effect on Thyroid 2Health News:VOICE study will continue as it considers what action to take after results of 2 trials 2Health News:VOICE study will continue as it considers what action to take after results of 2 trials 3Health News:VOICE study will continue as it considers what action to take after results of 2 trials 4Health News:'Swine Flu' Shot May Be Cleared of Guillain-Barre Charges 2Health News:State of the Science in the Prevention and Management of Osteoarthritis-A Conference for Nurses 2
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
... MVR knife. 1.1 mm (19G) with a 1.38 ... Cannula (5/bx, 1 bx/ca). State-of-the-art manufacturing and quality ... precise. Sure grip handles have a ridge indicating ... fluid tight incision for self-sealing wounds. Gauge size ...
For use in cleaning soft contact lenses. Sensitive Eyes daily cleaner loosens and removes accumulations of film, deposits, and debris from soft contact lenses. Use with heat, chemical, and hydrogen p...
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
Medicine Products: